JP2013532976A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013532976A5 JP2013532976A5 JP2013516795A JP2013516795A JP2013532976A5 JP 2013532976 A5 JP2013532976 A5 JP 2013532976A5 JP 2013516795 A JP2013516795 A JP 2013516795A JP 2013516795 A JP2013516795 A JP 2013516795A JP 2013532976 A5 JP2013532976 A5 JP 2013532976A5
- Authority
- JP
- Japan
- Prior art keywords
- domain
- complementary
- oligoribonucleotide
- domains
- free
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 230000000295 complement effect Effects 0.000 claims description 46
- 108091027075 5S-rRNA precursor Proteins 0.000 claims description 26
- 229930010555 Inosine Natural products 0.000 claims description 21
- UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 claims description 21
- 229960003786 inosine Drugs 0.000 claims description 21
- 101000831496 Homo sapiens Toll-like receptor 3 Proteins 0.000 claims description 20
- 102100024324 Toll-like receptor 3 Human genes 0.000 claims description 20
- 239000000556 agonist Substances 0.000 claims description 17
- UHDGCWIWMRVCDJ-UHFFFAOYSA-N 1-beta-D-Xylofuranosyl-NH-Cytosine Natural products O=C1N=C(N)C=CN1C1C(O)C(O)C(CO)O1 UHDGCWIWMRVCDJ-UHFFFAOYSA-N 0.000 claims description 16
- UHDGCWIWMRVCDJ-PSQAKQOGSA-N Cytidine Natural products O=C1N=C(N)C=CN1[C@@H]1[C@@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-PSQAKQOGSA-N 0.000 claims description 16
- UHDGCWIWMRVCDJ-ZAKLUEHWSA-N cytidine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-ZAKLUEHWSA-N 0.000 claims description 16
- 239000002773 nucleotide Substances 0.000 claims description 11
- 108091033319 polynucleotide Proteins 0.000 claims description 10
- 102000040430 polynucleotide Human genes 0.000 claims description 10
- 125000003729 nucleotide group Chemical group 0.000 claims description 9
- 229910052739 hydrogen Inorganic materials 0.000 claims description 5
- 239000001257 hydrogen Substances 0.000 claims description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 6
- 201000010099 disease Diseases 0.000 claims 3
- 208000035475 disorder Diseases 0.000 claims 3
- 230000001404 mediated effect Effects 0.000 claims 3
- 230000004936 stimulating effect Effects 0.000 claims 3
- 241000124008 Mammalia Species 0.000 claims 2
- 108020000411 Toll-like receptor Proteins 0.000 claims 2
- 102000002689 Toll-like receptor Human genes 0.000 claims 2
- 239000000427 antigen Substances 0.000 claims 2
- 102000036639 antigens Human genes 0.000 claims 2
- 108091007433 antigens Proteins 0.000 claims 2
- 230000000694 effects Effects 0.000 claims 2
- 229960005486 vaccine Drugs 0.000 claims 2
- 108020000948 Antisense Oligonucleotides Proteins 0.000 claims 1
- 108010041986 DNA Vaccines Proteins 0.000 claims 1
- 229940021995 DNA vaccine Drugs 0.000 claims 1
- 108020004459 Small interfering RNA Proteins 0.000 claims 1
- 239000002671 adjuvant Substances 0.000 claims 1
- 239000013566 allergen Substances 0.000 claims 1
- 229960004784 allergens Drugs 0.000 claims 1
- 239000005557 antagonist Substances 0.000 claims 1
- 239000003242 anti bacterial agent Substances 0.000 claims 1
- 229940088710 antibiotic agent Drugs 0.000 claims 1
- -1 antibodies Substances 0.000 claims 1
- 239000000074 antisense oligonucleotide Substances 0.000 claims 1
- 238000012230 antisense oligonucleotides Methods 0.000 claims 1
- 230000000139 costimulatory effect Effects 0.000 claims 1
- 229940127089 cytotoxic agent Drugs 0.000 claims 1
- 239000002254 cytotoxic agent Substances 0.000 claims 1
- 231100000599 cytotoxic agent Toxicity 0.000 claims 1
- 229910052805 deuterium Inorganic materials 0.000 claims 1
- 125000004431 deuterium atom Chemical group 0.000 claims 1
- 238000001415 gene therapy Methods 0.000 claims 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 1
- 230000028993 immune response Effects 0.000 claims 1
- 229940043355 kinase inhibitor Drugs 0.000 claims 1
- 108091070501 miRNA Proteins 0.000 claims 1
- 239000002679 microRNA Substances 0.000 claims 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 102000004196 processed proteins & peptides Human genes 0.000 claims 1
- 108090000765 processed proteins & peptides Proteins 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 239000002924 silencing RNA Substances 0.000 claims 1
- 238000006467 substitution reaction Methods 0.000 claims 1
- 239000013598 vector Substances 0.000 claims 1
- 238000003795 desorption Methods 0.000 description 3
- NYHBQMYGNKIUIF-UUOKFMHZSA-N Guanosine Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O NYHBQMYGNKIUIF-UUOKFMHZSA-N 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- MIKUYHXYGGJMLM-GIMIYPNGSA-N Crotonoside Natural products C1=NC2=C(N)NC(=O)N=C2N1[C@H]1O[C@@H](CO)[C@H](O)[C@@H]1O MIKUYHXYGGJMLM-GIMIYPNGSA-N 0.000 description 1
- NYHBQMYGNKIUIF-UHFFFAOYSA-N D-guanosine Natural products C1=2NC(N)=NC(=O)C=2N=CN1C1OC(CO)C(O)C1O NYHBQMYGNKIUIF-UHFFFAOYSA-N 0.000 description 1
- 229940029575 guanosine Drugs 0.000 description 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US35854310P | 2010-06-25 | 2010-06-25 | |
| US61/358,543 | 2010-06-25 | ||
| US41948810P | 2010-12-03 | 2010-12-03 | |
| US61/419,488 | 2010-12-03 | ||
| US201161435434P | 2011-01-24 | 2011-01-24 | |
| US61/435,434 | 2011-01-24 | ||
| PCT/US2011/041796 WO2012027017A2 (en) | 2010-06-25 | 2011-06-24 | Novel agonists of toll-like receptor 3 and methods of their use |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013532976A JP2013532976A (ja) | 2013-08-22 |
| JP2013532976A5 true JP2013532976A5 (cg-RX-API-DMAC7.html) | 2014-09-04 |
| JP6076899B2 JP6076899B2 (ja) | 2017-02-08 |
Family
ID=45556324
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013516795A Expired - Fee Related JP6076899B2 (ja) | 2010-06-25 | 2011-06-24 | Ｔｏｌｌ様レセプター３の新規アゴニストおよびその使用方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US8492358B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP2588143B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP6076899B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2802721C (cg-RX-API-DMAC7.html) |
| ES (1) | ES2620748T3 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2012027017A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2371834B1 (en) * | 2003-06-11 | 2016-02-17 | Idera Pharmaceuticals, Inc. | Stabilized immunomodulatory oligonucleotides |
| JP2014532400A (ja) * | 2011-10-31 | 2014-12-08 | リボックス・ゲーエムベーハー | 免疫賦活用の二本鎖ｒｎａ |
| TWI516593B (zh) | 2012-06-11 | 2016-01-11 | 義守大學 | 一種聚核苷酸用以製備減緩疼痛藥物之用途 |
| US11680244B2 (en) | 2015-05-20 | 2023-06-20 | The Regents Of The University Of California | Method for generating human dendritic cells for immunotherapy |
| IL258899B2 (en) | 2015-10-30 | 2024-03-01 | Univ California | Methods of generating t-cells from stem cells and immunotherapeutic methods using the t-cells |
| CN110022905B (zh) * | 2016-10-06 | 2024-02-06 | 安吉尼科分子传输公司 | 用于递送核酸佐剂的细菌小细胞和使用其的方法 |
| US20240384268A1 (en) * | 2021-04-08 | 2024-11-21 | Hudson Institute of Medical Research | Oligonucleotides |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20120115412A (ko) * | 2006-04-07 | 2012-10-17 | 이데라 파마슈티칼즈, 인코포레이티드 | Ｔｌｒ７ 및 ｔｌｒ８에 대한 안정화된 면역 조절성 ｒｎａ〔ｓｉｍｒａ〕 화합물 |
| JP2010520284A (ja) * | 2007-03-05 | 2010-06-10 | ユタ ステイト ユニバーシティ | Ｔｏｌｌ様受容体３（ＴＬＲ３）の限定アゴニスト |
| MX2009009530A (es) * | 2007-03-07 | 2010-05-19 | Nventa Biopharmaceuticals Corp | Composiciones de acidos nucleicos cerrados bicatenarios. |
| JP2011518116A (ja) | 2008-02-21 | 2011-06-23 | ユニバーシティ オブ ケンタッキー リサーチ ファウンデーション | トール様受容体３拮抗薬としての超小型ｒｎａ |
| SI2340307T1 (sl) * | 2008-10-23 | 2016-02-29 | Hemispherx Biopharma, Inc. | Dvoverižne ribonukleinske kisline z robustno fizikalno-kemijsko strukturo in zelo specifično biološko aktivnostjo |
| CN102361981A (zh) | 2009-02-10 | 2012-02-22 | 艾德拉药物股份有限公司 | Tlr7的合成rna基激动剂 |
-
2011
- 2011-06-24 EP EP11820310.8A patent/EP2588143B1/en not_active Not-in-force
- 2011-06-24 US US13/168,494 patent/US8492358B2/en not_active Expired - Fee Related
- 2011-06-24 WO PCT/US2011/041796 patent/WO2012027017A2/en not_active Ceased
- 2011-06-24 ES ES11820310.8T patent/ES2620748T3/es active Active
- 2011-06-24 CA CA2802721A patent/CA2802721C/en active Active
- 2011-06-24 JP JP2013516795A patent/JP6076899B2/ja not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013532976A5 (cg-RX-API-DMAC7.html) | ||
| Bates et al. | G-quadruplex oligonucleotide AS1411 as a cancer-targeting agent: Uses and mechanisms | |
| JP2024045156A (ja) | 十分に安定化された非対称ｓｉｒｎａ | |
| Zhou et al. | Aptamers: A promising chemical antibody for cancer therapy | |
| JP6697384B2 (ja) | 予防的および治療的使用のための免疫刺激剤としての球状の核酸ベース構築物 | |
| Sun et al. | Oligonucleotide aptamers: new tools for targeted cancer therapy | |
| US20160194642A1 (en) | Spherical nucleic acid-based constructs as immunoregulatory agents | |
| ES3046884T3 (en) | Use of aptamers in therapy and/or diagnosis of autoimmune diseases | |
| JP2010535242A5 (cg-RX-API-DMAC7.html) | ||
| CA2792942A1 (en) | Novel single chemical entities and methods for delivery of oligonucleotides | |
| Hu et al. | TLS11a aptamer/CD3 antibody anti-tumor system for liver cancer | |
| KR20130028917A (ko) | Ngf에 대한 압타머 및 그 용도 | |
| He et al. | Intravenous senescent erythrocyte vaccination modulates adaptive immunity and splenic complement production | |
| Iqbal | Aptamers as an emerging player in biology | |
| US10093934B2 (en) | SDF-1 binding nucleic acids and the use thereof in cancer treatment | |
| US20170233737A1 (en) | Means and Methods for the Treatment of Nephropathy | |
| US11371045B2 (en) | Method of modulating the number and the distribution of tumor-infiltrating leukocytes in tumors | |
| DIXIT et al. | a Review on Aptamers in Gene Therapy and Their Applications | |
| KR20240038974A (ko) | 바이러스 감염 및 암의 예방 및 치료를 위한 변형된 t 세포 수용체 | |
| WO2022104006A9 (en) | Gpc3 aptamers and variants and use thereof | |
| Yagi et al. | 554. Prevalence of Neutralizing Antibodies Against Adeno-Associated Virus 2, 8 and 9 in Non-Human Primate Colonies | |
| HK1184699B (en) | Sdf-1 binding nucleic acids and the use thereof in cancer treatment |